SEATTLE CHILDRENS HOSPITAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $93.1M
- Transactions
- 4,560
- Companies
- 40
- Average per transaction
- $20,415
Who reported the payments
| Bristol Myers Squibb | $33,022,533 |
| CSL Behring | $16,631,286 |
| E.r. Squibb & Sons, L.L.C. | $13,117,652 |
| Pfizer | $3,767,671 |
| Medtronic | $2,700,902 |
| Jazz Pharmaceuticals Inc. | $2,342,253 |
| Merck | $1,742,599 |
| Regeneron | $1,508,950 |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,385,294 |
| Vertex | $1,315,204 |
| Sarepta Therapeutics, Inc. | $1,229,660 |
| Eli Lilly | $1,002,494 |
| Rhythm Pharmaceuticals, Inc. | $873,975 |
| AbbVie | $870,892 |
| PTC Therapeutics, Inc. | $775,643 |
| AstraZeneca | $700,818 |
| Ultragenyx Pharmaceutical Inc. | $583,195 |
| Gilead | $541,792 |
| Neurocrine Biosciences, Inc. | $537,175 |
| Novartis | $534,766 |
| Biomarin Pharmaceutical Inc. | $532,643 |
| Sanofi | $510,820 |
| Biogen | $424,165 |
| Soleno Therapeutics, Inc. | $415,628 |
| Daiichi Sankyo Inc. | $405,267 |
| Shire North American Group Inc | $379,444 |
| Acadia Pharmaceuticals Inc | $332,963 |
| Janssen Research & Development, LLC | $330,521 |
| Bayer | $291,843 |
| Sanofi US Services Inc. | $252,465 |
| Roche Products Limited | $236,767 |
| Genentech, Inc. | $233,249 |
| Modernatx, Inc. | $179,537 |
| Day One Biopharmaceuticals | $160,229 |
| Edwards Lifesciences | $141,975 |
| Eisai Inc. | $133,437 |
| Ascendis Pharma Endocrinology Inc | $129,299 |
| Immedica Pharma US, Inc. | $124,580 |
| Mirum Pharmaceuticals, Inc. | $119,963 |
| Supernus Pharmaceuticals, Inc. | $107,284 |